Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights
Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights – Company reiterates
June 22, 2022
Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights – Company reiterates
Yale’s Department of Psychiatry Chair to Join Clearmind Medicine Dr. John H. Krystal, world-leading expert
Ceruvia Lifesciences Submits FDA Investigational New Drug Application for NYPRG-101 Migraine Prevention Program Based on
Awakn Life Sciences Reports Results for Quarter Ended April 30, 2022 Awakn delivered revenue growth
Small Pharma Reports Highlights for the Fiscal Year Ended February 28, 2022 – Reporting its
Numinus completes acquisition of Novamind and announces executive appointment Numinus Wellness (NUMI) completed its acquisition
Cybin (CYBN) received a ‘Buy’ rating from two major analysts, Roth Capital and Canaccord Genuity, following the announcement that
Optimi Health Finalizes Partnership and Psilocybin Supply Agreement With ATMA Journey Centers Strategic partnership will
Cybin Acquires DMT Clinical Study from Entheon Biomedical 06/07/2022 — Acquisition of largest Phase 1
Doseology Opens to American Investors Vernon, British Columbia, June 1, 2022 – Doseology Sciences Inc. (CSE: MOOD) (FSE: VU7)
Lennham Pharmaceuticals Announces Issuance of U.S. Patent Covering Methods of Administering Psilocybin and Psilocin Patent
Wesana Announces First Quarter 2022 Financial Results CHICAGO and TORONTO, May 31, 2022 (GLOBE NEWSWIRE)
Novamind Reports Fiscal Q3 2022 Financial Results and Operating Highlights Record high quarterly revenue of
Optimi Health Signs Psilocybin Supply Agreement With Halucenex Life Sciences Inc. Halucenex to receive recently
Optimi Health Acquires Extensive Catalog of Psychedelic and Functional Mushroom Genetics Optimi Health (OPTI) acquired
atai Life Sciences Reports First Quarter 2022 Financial Results and Business Update atai Life Sciences
MindMed Reports First Quarter 2022 Financial Results and Business Highlights MindMed (MNMD) announced Q1 results
Mydecine Announces First Quarter 2022 Financial Results and Highlights Mydecine (MYCO) announced a $5.6M net
Field Trip and Nue Life Are Collaborating To Bring Psychedelic Therapy Into the Home Field
Psycheceutical Brings on Original Shark from ‘Shark Tank,’ Kevin Harrington, as Investor and Strategic Advisor
FSD Pharma Closes CAD$16.4 Million Sale of Non-core Assets FSD Pharma (HUGE) sold its assets
PharmAla Biotech Expands MDMA Distribution with CCrest Labs PharmAla Biotech (MDMA) signed a distribution agreement
Wesana Announces Singular Focus on Drug Development Prompting a Strategic Review of its Clinics and
Optimi Health Opens Canada’s Largest GMP-Grade Licensed Psilocybin Cultivation Facility Optimi Health (OPTI) opened the